Meropenem Acs Dobfar (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the cross‑linking of peptidoglycan strands. This inhibition prevents cell‑wall synthesis, leading to osmotic instability and bacterial cell death. Its structure also confers resistance to many β‑lactamases, expanding its activity against resistant organisms.

The dosing regimen for Meropenem Acs Dobfar is determined by the prescribing clinician based on the type and severity of infection, renal function, and patient weight. Healthcare professionals calculate the appropriate intravenous infusion rate and duration according to established clinical guidelines.

Safety data for meropenem in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem and ertapenem but offers broader activity against Pseudomonas aeruginosa and certain resistant Gram‑negative organisms. It is also more stable against many β‑lactamases. Choice among carbapenems depends on infection type, pathogen susceptibility, patient renal function, and safety considerations.

Meropenem Acs Dobfar should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. Once reconstituted, the solution should be used within the time frame specified by the manufacturer and kept under the same temperature conditions during administration.

The product is supplied for intravenous infusion. It is typically diluted in an appropriate compatible solution and administered over a prescribed period, often 30 minutes to 1 hour, depending on the clinical protocol. Administration should be performed by qualified healthcare personnel in a controlled setting.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Clinicians should monitor patients closely for neurological changes, allergic signs, and persistent diarrhea.

Meropenem is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving interacting medications that could increase toxicity.